ALEXANDRA DRAKAKI, MD, PHD UNIVERSITY OF CALIFORNIA LOS ANGELES gives an overview of A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer at the 2017 Kidney Cancer Association symposium in Miami, FL.
A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer
